{"filing":{"accession_number":"0001606498-26-000093","cik":"0001606498","ticker":"AVNS","company_name":"AVANOS MEDICAL, INC.","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"avns-20260714.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1606498/000160649826000093/avns-20260714.htm"},"events":[{"id":17968,"run_id":16121,"accession_number":"0001606498-26-000093","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"This Item 8.01 discloses a supplement to the definitive proxy statement for a merger transaction. The core event is the pending merger between Avanos and A-AV Holdco I, Inc., with stockholder approval scheduled for July 22, 2026. Although the filing addresses litigation and supplemental disclosures, the material event is the merger activity itself—a change of control transaction that was previously disclosed on April 13, 2026, and is now being supplemented in response to stockholder litigation and demand letters. The supplement updates key merger-related disclosures including financial forecasts, valuation analyses, and conflict-of-interest information, all central to the merger transaction.","company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16635,"accession_number":"0001606498-26-000093","item_number":"8.01","item_title":"Other Events","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"This Item 8.01 discloses a supplement to the definitive proxy statement for a merger transaction. The core event is the pending merger between Avanos and A-AV Holdco I, Inc., with stockholder approval scheduled for July 22, 2026. Although the filing addresses litigation and supplemental disclosures, the material event is the merger activity itself—a change of control transaction that was previously disclosed on April 13, 2026, and is now being supplemented in response to stockholder litigation and demand letters. The supplement updates key merger-related disclosures including financial forecasts, valuation analyses, and conflict-of-interest information, all central to the merger transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T10:05:42.603132+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16635,"accession_number":"0001606498-26-000093","item_number":"8.01","item_title":"Other Events","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"This Item 8.01 discloses a supplement to the definitive proxy statement for a merger transaction. The core event is the pending merger between Avanos and A-AV Holdco I, Inc., with stockholder approval scheduled for July 22, 2026. Although the filing addresses litigation and supplemental disclosures, the material event is the merger activity itself—a change of control transaction that was previously disclosed on April 13, 2026, and is now being supplemented in response to stockholder litigation and demand letters. The supplement updates key merger-related disclosures including financial forecasts, valuation analyses, and conflict-of-interest information, all central to the merger transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T10:05:42.603132+00:00","company_name":"AVANOS MEDICAL, INC.","ticker":"AVNS","filing_date":"2026-07-14"}]}